Aarti Drugs Limited has reported its financial results for the second quarter of FY25, showing a decline in both revenue and profit compared to the same period last year.
Key Financial Highlights (Q2 FY25 vs Q2 FY24):
- Revenue from operations: ₹543.09 crore, down 6.3% from ₹577.54 crore in Q2 FY24.
- Total income: ₹543.47 crore, down 6.2% from ₹578.28 crore in Q2 FY24.
- Profit before tax (PBT): ₹40.99 crore, down 12.5% from ₹46.83 crore in the same quarter last year.
- Profit after tax (PAT): ₹30.39 crore, down 12.1% from ₹34.58 crore in Q2 FY24.
- Total expenses: ₹502.58 crore, down slightly by 5.4% compared to ₹531.45 crore in Q2 FY24.
Other Metrics:
- Tax expenses: ₹10.50 crore in Q2 FY25, down from ₹12.25 crore in Q2 FY24, reflecting a 14.3% decline.
- Earnings per share (EPS): ₹3.33 in Q2 FY25, down from ₹3.75 in the same quarter last year, representing an 11.2% decrease.
Aarti Drugs’ performance in Q2 FY25 reflects the challenging market conditions and the impact of lower demand in certain segments. The company continues to focus on managing costs to maintain profitability amidst declining revenues.
